Follow up after percutaneous MR-guided cryoablation of Small Renal Masses.

Follow up after percutaneous MR-guided cryoablation of Small Renal Masses. - FU after cryoablation of small renal masses (SRM).

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40801

Enrollment

Registered

2014-08-04

Start date

2015-02-26

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney cancer Renal cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: >50 years of age; At least one untreated T1a tumour of one kidney (tumour

Exclusion criteria

Exclusion criteria: Relative contra indications for MR imaging (metal device/foreign bodies, claustrophobia); Pregnancy or breast feeding; Known hypersensitivity or HACA against Girentuximab.

Design outcomes

Primary

Measure	Time frame
Positive and negative predictive value of MRI and Indium-111-Girentuximab-DOTA SPECT 4-6 weeks after intervention.	—

Secondary

Measure	Time frame
Residual and recurrent free survival at 3 months follow up.	—

Countries

Netherlands

Outcome results